DeepCure, developer of small molecule therapeutics using an AI-enabled drug discovery platform, raised $40 million in Series A funding.
The round was led by Morningside Ventures with participation from existing investors TLV Partners, Sapir Venture Partners and Benon Group Ltd.
DeepCure said the Series A brings its total raise to $47 million.
WHAT IT DOES
The company uses its AI engine to develop...
